arginyl-glycyl-aspartyl-serine has been researched along with Osteosarcoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, TF; Yang, RS | 1 |
1 other study(ies) available for arginyl-glycyl-aspartyl-serine and Osteosarcoma
| Article | Year |
|---|---|
Rhodostomin inhibits the transforming growth factor-beta1-enhanced adhesion activity of ROS 17/2.8 osteosarcoma cells.
Topics: Animals; Cell Adhesion; Extracellular Matrix; Oligopeptides; Osteosarcoma; Peptides; Rats; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Cells, Cultured | 2000 |